Clinical Trial DesignNebokitug's single pivotal Phase 3 study is expected to not require a liver biopsy, using a clinical events-based endpoint, making it less costly and easier to enroll.
Regulatory ApprovalThe feedback from FDA supports a single Phase 3 for full approval based on events relating to disease progression, with no biopsy endpoint, which is seen as a favorable result.
Strategic PartnershipsChemomab is in active strategic partnering discussions to advance the program into Phase 3, which is expected to bring the asset forward significantly.